Key facts
- What it is: a bacterium that uses mucin, a component of intestinal mucus.
- What GI-MAP measures: its DNA in a stool sample, alongside other gut markers.
- What a flag cannot establish: a damaged gut barrier, the cause of symptoms or a need for treatment.
- What research shows: some encouraging human findings, alongside important negative results and unanswered questions.
On this page: What it does · Low and high results · Human research · Supplements · Next steps
What is Akkermansia, and what does it do?
Akkermansia muciniphila is a species of bacterium found in the gut mucus layer. It breaks down mucin, a sugar-containing protein in mucus, and participates in an ecosystem shared with other microbes. Scientists study this relationship because mucus helps separate the intestinal lining from the contents of the gut. [1]
“Mucin-degrading” describes how the bacterium obtains nutrients. It does not mean that detecting it proves your gut lining is being damaged. Equally, calling it a “beneficial” or “keystone” microbe does not mean that more is always better. Effects depend on the surrounding biology; a stool number is not a direct test of that process.
Studies have associated Akkermansia abundance with metabolic health, and researchers have tested whether giving specific preparations changes health outcomes. Those are different questions: an association in a population cannot tell you what caused an individual’s symptoms. [2]
Understanding Akkermansia on a GI-MAP report
GI-MAP uses quantitative PCR (qPCR) to measure selected DNA targets in stool. The laboratory lists Akkermansia among its commensal or keystone bacteria. Microbial quantities are reported as genome equivalents per gram of stool, estimated from DNA measurement. [3]
Use the units and reference interval printed on your own report. A qPCR quantity is different from the percentage of a microbial community reported by some sequencing tests. You cannot directly compare the two numbers.
Low Akkermansia muciniphila
A low flag means the measured amount is below that report’s reference interval. It does not, on its own, diagnose a deficiency, “leaky gut,” diabetes or the cause of bloating. Your diet, medications, health history and reason for testing belong in the discussion with your clinician.
Below the detection limit
A result marked “<dl” is below the assay’s detectable limit in the submitted sample. It does not prove that Akkermansia is completely absent from your gut. A detection threshold is also different from a treatment threshold.
High Akkermansia muciniphila
A high flag describes a quantity outside that report’s reference interval. It is not a diagnosis of an infection or an autoimmune condition, and it does not establish that the bacterium needs to be reduced. Avoid interpreting “high” as either automatically harmful or automatically protective.
What is a normal Akkermansia level?
There is no single number that can be transferred between every test method and used to define a healthy person. An international consensus on microbiome testing specifically cautions that evidence is insufficient for strict healthy ranges of species’ relative abundance. That statement concerns relative abundance and should not be confused with GI-MAP’s qPCR units. A laboratory reference interval and a clinically validated treatment cutoff are different concepts. [4]
The Akkermansia result does not directly measure intestinal permeability, mucus thickness or metabolic function. Read it with the rest of the report and the clinical question. Our GI-MAP interpretation guide and sample report explain how results are presented.
Akkermansia benefits: what human studies actually show
The evidence now includes human trials, so it is no longer accurate to describe this area using animal research alone. The findings still need to be read with their study populations and limitations.
- 2019 pilot: 40 adults with overweight or obesity and insulin resistance enrolled; 32 completed three months. The pasteurized preparation improved some metabolic measures compared with placebo. This small exploratory study did not establish a general treatment recommendation. [2]
- 2026 weight maintenance trial: 90 adults first followed an eight-week diet to lose at least 8% of body weight. During the subsequent 24-week maintenance phase, the pasteurized MucT group regained an average 1.2 kg versus 3.2 kg with placebo. This studied a specific preparation after substantial diet-induced weight loss; it does not show that every Akkermansia product produces weight loss. [5]
- 2026 metabolic syndrome trial: in 142 adults, the primary measure of whole-body insulin sensitivity did not improve compared with placebo after four months. Exploratory analyses suggested benefits in some subgroups, including people with low baseline Akkermansia. Those analyses need confirmation and do not establish a GI-MAP cutoff for treatment. [6]
Some authors of these trials have disclosed commercial or patent interests in Akkermansia products. That does not invalidate the findings, but it makes independent replication and attention to primary outcomes particularly useful. The studies also do not establish long-term benefit or safety for every population. [2] [5] [6]
Akkermansia probiotics, side effects and low results
Products containing live bacteria and pasteurized preparations are not interchangeable. Pasteurization means the bacteria are no longer alive; evidence for one strain, preparation and study population should not be assumed to apply to every product sold under the Akkermansia name.
A low stool result alone is not a reason to start a supplement. Although early trials reported tolerability in the adults studied, that does not establish safety for children, pregnancy, people with a weakened immune system or every gastrointestinal condition. Discuss the actual product and your circumstances with a licensed clinician.
Can food, prebiotics or a diet raise Akkermansia?
Diet can influence the gut microbiome, but changing one reported number is not itself proof of a health benefit. There is no GI-MAP-based food plan established by the trials above. If you have dietary restrictions or ongoing symptoms, discuss a sustainable eating pattern with your clinician or dietitian instead of choosing a restrictive diet to chase one marker.
Does Akkermansia increase GLP-1?
The 2026 metabolic syndrome trial reported GLP-1 findings in exploratory analyses, while its primary insulin-sensitivity endpoint was negative. A hormone response in a study does not establish that an Akkermansia supplement has the same effects as a prescribed GLP-1 medicine or can replace it. [6]
What should you do with your result?
Bring the complete report and a list of symptoms, medications and supplements to your clinician. Ask what the finding adds, whether another explanation needs assessment, and whether any proposed change has evidence for your circumstances.
For example, low Akkermansia with bloating establishes a laboratory finding alongside a symptom; it does not establish that one caused the other. If you already have a condition such as Crohn’s disease, the result does not determine disease activity or justify changing prescribed treatment.
Persistent or worsening symptoms deserve medical assessment. Blood in stool, severe abdominal pain or unexplained weight loss should not be managed by trying to adjust a microbiome marker.
Frequently asked questions
What is Akkermansia muciniphila?
Akkermansia muciniphila is a bacterium that can live in the intestinal mucus layer and use mucin as a food source. Researchers study its relationship with gut and metabolic health; its stool level alone is not a measure of overall health.
What does low Akkermansia muciniphila mean?
A low result means the measured amount is below that laboratory report’s reference interval. It does not by itself diagnose a deficiency, explain symptoms or establish that you need a supplement. A below-detection result also does not prove complete absence from your gut.
Does GI-MAP measure Akkermansia?
Yes. GI-MAP uses qPCR to report Akkermansia muciniphila DNA in stool among the commensal or keystone bacteria. This measurement does not directly test mucus thickness, intestinal permeability or insulin sensitivity.
Does a low result mean I should take an Akkermansia probiotic?
No. Human trials have studied particular preparations in selected groups, with mixed findings. They have not established a GI-MAP cutoff for selecting a supplement. Discuss the reason for testing and any proposed treatment with a licensed clinician.
Want to see where Akkermansia appears on the panel?
Start with the sample report and discuss whether the test fits the question you need answered.
See a sample report → View GI-MAP StandardSources
- Duke University School of Medicine (2023). Scientists Unlock Secrets of Gut Bacteria Linked to Heart Health. Research institution’s account of its mechanistic study.
- Depommier et al. (2019). Supplementation with Akkermansia muciniphila in overweight and obese human volunteers. Randomized pilot trial.
- Diagnostic Solutions Laboratory. GI-MAP Interpretive Guide, edition marked 042826; methods, commensal bacteria and report key. Manufacturer documentation.
- Porcari et al. (2025; first published online 2024). International consensus statement on microbiome testing in clinical practice.
- Mount et al. (2026). Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity. Randomized trial.
- Suenaert et al. (2026). Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome. Randomized trial.
Sources accessed October 16, 2026.